The risk for tuberculosis appearsto be lower with etanercept compared with the use of the mAb formsof TNF inhibition, suggesting that the greater the antigranulomaforming effect, the greater the risk for granulomatous infections.[4]The differential effects of these agents are likely mediatedthrough varying efficacy in eliminating immune cells bearingtransmembrane TNF-α.[4]. Here, TNF is linked to tuberculosis.